Morgan Stanley Abcam PLC Transaction History

Morgan Stanley

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	SELL	$21.54 - $24.41 $46.3 Million - $52.5 Million	-2,151,256 Reduced 55.3%	1,738,890 $39.4 Million
Q2 2023 Aug 14, 2023	SELL	$12.62 - $24.47 $18.3 Million - $35.5 Million	-1,449,513 Reduced 27.15%	3,890,146 $95.2 Million
Q1 2023 May 15, 2023	SELL	$12.98 - $17.1 $28.3 Million - $37.2 Million	-2,177,320 Reduced 28.97%	5,339,659 $71.9 Million
Q4 2022 Feb 14, 2023	BUY	$13.92 - $17.0 $99.4 Million - $121 Million	7,143,012 Added 1910.06%	7,516,979 $117 Million
Q3 2022 Nov 14, 2022	SELL	$13.36 - $16.75 $20,587 - $25,811	-1,541 Reduced 0.41%	373,967 $5.61 Million
Q2 2022 Oct 27, 2022	BUY	$12.69 - $19.25 $4.59 Million - $6.96 Million	361,590 Added 2598.0%	375,508 $5.43 Million
Q2 2022 Aug 15, 2022	BUY	$12.69 - $19.25 $4.59 Million - $6.96 Million	361,590 Added 2598.0%	375,508 $5.43 Million
Q1 2022 Oct 27, 2022	SELL	$15.5 - $23.89 $5.6 Million - $8.64 Million	-361,590 Reduced 96.29%	13,918 $254,000
Q1 2022 May 13, 2022	SELL	$15.5 - $23.89 $15.9 Million - $24.5 Million	-1,025,212 Reduced 98.66%	13,918 $254,000
Q4 2021 Feb 14, 2022	BUY	$20.04 - $23.84 $3.2 Million - $3.81 Million	159,829 Added 18.18%	1,039,130 $24.5 Million
Q3 2021 Nov 15, 2021	BUY	$17.38 - $21.54 $15.3 Million - $18.9 Million	879,301 New	879,301 $17.8 Million

1.03M

Ticker ABCM
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 229,044,992
Description
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.